UPDATE: Cantor Fitzgerald Starts I-Mab (IMAB) at Overweight

(updating comment)

Cantor Fitzgerald analyst Louise Chen initiates coverage on I-Mab (NASDAQ: IMAB) with a Overweight rating and a price target of $50.00.

The analyst comments "IMAB is unique among China-based biotech companies because it exclusively focuses on the discovery, development and commercialization, of first-in-class/best-in-class drugs. The next important catalysts for IMAB include: 1) data validating TJC4's clinical differentiation (3Q20E), 2) TJM2 COVID-19 data (3Q20E), 3) TJD5, safety, PK and biomarker data (4Q20E), 4) TJ301 Phase 2 topline data in UC (end-FY20E/early-FY21E) and 5) global partnerships (FY20E onward)."

For an analyst ratings summary and ratings history on I-Mab click here. For more ratings news on I-Mab click here.

Shares of I-Mab closed at $28.24 yesterday.

You May Also Be Interested In

• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform